European Patent grants for IMP731 antibody
SYDNEY-
August 26, 2016 Prima BioMed (ASX:
PRR; NASDAQ: PBMD) announces the granting of patent number 2142210 entitled
“Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or
prevention of organ transplant rejection and autoimmune disease” by the
European Patent Office.
The patent relates to Prima’s IMP731
antibody, originally developed by Immutep SAS. The granted claims provide
protection for specific sequences of anti-LAG-3 antibodies and their use in
depleting LAG-3+ T cells by complement dependent cytotoxicity and
antibody-dependent cell cytotoxicity.
Rights for the development of the IMP731
antibody were granted in December 2010 to GSK, which has commenced
first-in-human clinical trials of the proprietary antibody.
Source: http://blog.ip.com/2016/08/european-patent-grants-for-imp731-antibody/